Replimune Group Stock Price, News & Analysis

Replimune Group, a clinical-stage biotechnology firm, presented key updates on its ongoing trials at the 2022 ASCO Annual Meeting from June 3-7, in Chicago.

Highlights include:

• RP1 results from the IGNYTE study, combining RP1 with Opdivo.
• Ongoing trials for RP2 and RP3 programs.

The CERPASS trial aims to evaluate treatment efficacy in advanced cutaneous squamous cell carcinoma, enrolling 180 patients. This study represents a significant step in Replimune's mission to innovate cancer therapies.

Replimune Group, Inc. reported financial results for the fiscal year ending March 31, 2022, indicating a net loss of $118.0 million, up from $80.9 million the previous year. Total research and development expenses reached $79.5 million, an increase from $56.8 million, largely due to expanding clinical trials. The company has a strong cash position of $395.7 million which it believes will fund operations into the second half of 2024. Enrollment in key clinical trials is ongoing, with top line data from significant trials expected in late 2022 and early 2023.

Replimune Group (NASDAQ: REPL) announced promising updates from its Phase 2 IGNYTE trial focusing on RP1, its oncolytic immunotherapy, for melanoma and non-melanoma skin cancers. Initial data reveals that RP1 combined with Opdivo continues to yield deep and durable responses, particularly in anti-PD1 failed patients. New data for RP1 as monotherapy in solid organ transplant recipients shows early clinical activity. The company has announced a broad Phase 2 development plan for RP2/RP3 targeting hard-to-treat tumors, emphasizing its commitment to addressing significant unmet medical needs in oncology.

Replimune Group Inc. (NASDAQ: REPL) will host an investor event on March 30, 2022, at 8:00 AM ET to present updated data from its Phase 2 IGNYTE clinical trial in non-melanoma skin cancer and melanoma. New data from the ongoing trial in anti-PD1 failed NMSC will also be shared, alongside findings from the ARTACUS clinical trial involving RP1 as monotherapy for solid organ transplant recipients with skin cancer. The event will be accessible via live webcast on Replimune's website, with a replay available post-event.

Replimune Group, a clinical stage biotechnology company, announced that CEO Philip Astley-Sparke will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 8:40 AM ET. The event will take place virtually, and a webcast will be accessible on Replimune's website, with a replay available for 90 days post-conference. Replimune specializes in developing tumor-directed oncolytic immunotherapies using its proprietary RPx platform, aiming to enhance cancer treatment through innovative mechanisms.

Replimune Group Inc. (NASDAQ: REPL) reported its financial results for the third fiscal quarter ended December 31, 2021, revealing a net loss of $29.7 million, up from $21.8 million a year ago. Research and development expenses rose to $19.4 million, reflecting heightened clinical activities. The company holds $420.2 million in cash, expected to fund operations until mid-2024. Upcoming milestones include initial data releases from various clinical trials and an investor event in March 2022 to discuss commercial strategies and RP2/3 development plans.

Replimune Group Inc. (NASDAQ: REPL) announced the resignation of Otello Stampacchia, Ph.D., from its Board of Directors effective January 31, 2022. Dr. Stampacchia, a co-leader of Replimune’s seed financing, has decided to focus on his commitments at Omega Funds. CEO Philip Astley-Sparke expressed gratitude for Dr. Stampacchia’s contributions to Replimune's growth from inception to a leader in oncolytic immunotherapies. Replimune aims to innovate cancer treatment through its proprietary RPx platform, enhancing both local and systemic therapeutic effects.

Replimune Group (Nasdaq: REPL) provided a corporate update on January 10, 2022, highlighting the progress of its clinical trials for RP1, RP2, and RP3. The CERPASS trial for RP1 in cutaneous squamous cell carcinoma (CSCC) is on track for enrollment completion mid-year, leading to primary data analysis later. Interim data from the IGNYTE trial, assessing RP1's efficacy in anti-PD1 failed melanoma, is expected by late 2022. Replimune aims to expand RP2 and RP3 trials into diverse cancer types, with detailed development plans to be unveiled in Q1 2022.

Replimune Group, a clinical-stage biotechnology firm, has announced that its CEO, Philip Astley-Sparke, will present on January 10, 2022, at the 40th Annual J.P. Morgan Healthcare Conference. The event will be held virtually at 7:30 AM ET. A webcast will be accessible through Replimune’s website, with a replay available for 30 days. Founded in 2015, Replimune focuses on tumor-directed oncolytic immunotherapies, utilizing its proprietary RPx platform to enhance cancer treatment.